A **HBc183 - SRPK1**



MH^+_{calc}: 21,116 Da

m/z_{obs}: 21,103

B **HBc183 + SRPK1**



MH^+_{calc} for 6P: 21,597 Da

MH^+_{calc} for 8P: 21,757 Da

MH^+_{calc} for 7P: 21,677 Da

m/z_{obs}: 21,664

S5 Fig. MALDI-TOF MS characterization of HBc183 expressed in the absence vs. presence of SRPK1ΔNS1. Analyses were performed by Frederic Delolme (UMR5086 CNRS - Université Lyon 1, France) on a Sciex Voyager DE-PRO MALDI-TOF instrument, using saturated sinapic acid as matrix at a sample:matrix dilution of 1:100 (v/v). **(A) HBc183 expressed in the absence of SRPK1.** The observed m/z 21,103 for the dominant MH^+ peak fits best to the calculated MH^+ mass of 21,116 Da for unmodified HBc183 (including the N terminal Met). **(B) HBc183 expressed in the presence of SRPK1.** The observed m/z 21,664 for the dominant MH^+ peak fits best to the calculated MH^+ mass of 21,676 Da for HBc183 carrying 7 phosphoryl groups. While peak intensity is not directly correlated with abundance a rather homogeneous seven-fold phosphorylation status is supported by the uniform appearance of the HBc183 + SRPK1 protein in Phos-Tag SDS-PAGE (Fig 3) and the equal dominance of a seven-fold phosphorylated peptide representing just the CTD (Fig 4).